Koers Nanoform Finland Oyj Nasdaq Helsinki
Aandelen
FI4000330972
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 7,48 mln. 7,98 mln. | Omzet 2025 * | 14,6 mln. 15,56 mln. | Marktkapitalisatie | 184 mln. 196 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -15 mln. -15,99 mln. | Nettowinst (verlies) 2025 * | -11 mln. -11,72 mln. | EV/omzet 2024 * | 20,4 x |
Nettoliquiditeiten 2024 * | 31 mln. 33,04 mln. | Nettoliquiditeiten 2025 * | 21,34 mln. 22,74 mln. | EV/omzet 2025 * | 11,1 x |
K/w-verhouding 2024 * |
-11
x | K/w-verhouding 2025 * |
-15,4
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 61,6% |
Recentste transcriptie over Nanoform Finland Oyj
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Edward Hæggström
CEO | Chief Executive Officer | 55 | 01-01-15 |
Albert Häggström
DFI | Director of Finance/CFO | 53 | 01-01-15 |
Investor Relations Contact | - | 01-05-19 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chairman | 68 | 02-04-19 | |
Mads Laustsen
BRD | Director/Board Member | 67 | 01-01-19 |
Albert Häggström
DFI | Director of Finance/CFO | 53 | 01-01-15 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+0,17% | 42,86 mld. | |
+10,92% | 42,74 mld. | |
+44,30% | 41,36 mld. | |
-6,20% | 27,68 mld. | |
+5,23% | 25,15 mld. | |
-24,79% | 18,63 mld. | |
+26,69% | 12,37 mld. | |
-3,13% | 11,92 mld. | |
+6,57% | 11,21 mld. |